|
|
||||||||
1 Institut National de la Santé et de la Recherche Médicale U388, Institut Louis Bugnard, Centre Hospitalier Universitaire Rangueil, 31052 Toulouse; 2 Institut National de la Santé et de la Recherche Médicale U430, Hôpital Broussais, 75674 Paris Cedex 14, France
| |
ABSTRACT |
|---|
|
|
|---|
Bradykinin
B2 receptor knockout mice (B2
/
)
have been useful to study the role of bradykinin under pathological
conditions. With the use of these mice, it was shown that bradykinin
plays an important role in angiogenesis, heart failure, salt-induced hypertension, and kidney fibrosis. Data on the role of the bradykinin B2 receptor under physiological conditions using these mice
are controversial and scarce, because these mice have no typical
phenotype. For this reason, we have studied, under physiological
conditions, renal hemodynamics as well as a number of morphometric
glomerular parameters of B2
/
mice on a
homogenized genetic background and on mice bred in a pathogen-free
environment. Backcrossed B2
/
mice had
normal blood pressure and normal apparent renal hemodynamics and
morphology. However, reduced renal nitrite excretion and glomerular cGMP content were found, which was associated with a reduced glomerular capillary surface area. These differences had, however, no detectable effects on renal hemodynamics. These differences between
B2
/
and wild-type mice might become
important under pathological conditions as shown by a number of studies
using these bradykinin B2 receptor knockout mice.
kidney; hemodynamics; nitric oxide; backcross; genetic background
| |
INTRODUCTION |
|---|
|
|
|---|
THE
DEVELOPMENT of genetically engineered mice lacking the bradykinin
B2 receptor (B2
/
)
(4) has allowed to better define the physio(patho)logical actions of bradykinin. The nonapeptide bradykinin is generated by the
proteolytic action of the serine protease kallikrein from kininogen
(3). Pharmacological studies have shown that kinins exert
their biological effects through the activation of two
seven-transmembrane domain G protein-coupled receptors named
B1 and B2 receptor (20). The
natural agonist of the B2 receptor is bradykinin and its
degradation by a carboxypeptidase produces the B1 receptor agonist
[des-Arg9]bradykinin (20). The
B1 receptor is weakly detectable under physiological
conditions but is strongly expressed in pathological states
(16). The B2 receptor, which is constitutively
expressed, mediates most of the known effects of bradykinin.
It is now generally admitted that bradykinin plays an essential role in renal homeostasis (23, 24). In the kidney, the most pronounced effects of bradykinin are the reduction of vascular resistance (RVR), the increase in renal blood flow (RBF) with no change in the glomerular filtration rate (GFR), and augmentation of natriuresis and diuresis (2, 13, 27). These natriuretic and diuretic effects of bradykinin are due, at least in part, to the activation of B2 receptors in the medullary thick ascending limb of the loop of Henle (9).
B2
/
mice do not display a specific
phenotype. For example, because bradykinin is a well-known vasodilator
peptide, a higher blood pressure (BP) under basal conditions was
expected in B2
/
mice. However, the majority
of the papers studied thus far showed no difference in BP between
B2
/
and wild-type mice (1, 6,
18) except for one study, which reported a higher BP in the
B2
/
mice (15).
When fed a high-salt diet, B2
/
mice
developed salt-sensitive hypertension, which was absent in wild-type
mice. This salt-sensitive hypertension was associated with a reduced
RBF and an increased RVR (1). This salt-sensitive
hypertension was confirmed in another study using
B2
/
mice (15); however, renal
function was not studied. In contrast, a more recent study showed that
increasing dietary salt intake did not modify BP and RBF in
B2
/
mice, whereas the diet increased RBF in
wild-type mice (18).
As recently reviewed, it is now well admitted that differences in
genetic background of genetically modified mice leads to divergent
results between different laboratories (25). The observed differences for B2
/
mice might thus
originate in differences in the genetic background of the used mice
strains and therefore might not be due to the absence of the
B2 receptor. The current study was setup to investigate, under physiological conditions, renal hemodynamics as well as some
morphometric glomerular parameters of B2
/
mice on a homogenized genetic background and on mice bred in a
pathogen-free environment.
| |
MATERIALS AND METHODS |
|---|
|
|
|---|
Animals.
B2
/
mice were generously provided by Drs.
F. Hess and T. MacNeil (Merck; Rahway, NJ) (4).
B2
/
mice were originally on a mixed genetic
background (J129sv × C57Bl/6J). B2
/
mice were backcrossed for 10 generations against a C57Bl/6J background, and the homogeneity of the background was verified by microsatellite analysis (Nucleis; Angers, France; Table
1). Furthermore, mice were housed in a
pathogen-free environment.
|
Experimental protocols. Male mice at the age of 8 wk were used in these experiments, 10 mice in each group. Mice were maintained on a standard mouse chow and tap water. For the metabolic study, mice were housed individually in metabolic cages (Marty Technologie) in a temperature (20°C) and photoperiod (7 AM to 7 PM)-controlled room. They were allowed free access to standard chow and water. Food and water consumption and urine secretion were determined gravimetrically once a day for each mouse during 3 days. Nitrite concentrations in urine samples were determined colorimetrically (Roche Molecular Biochemicals; Meylan, France). Na+ and K+ concentrations were determined by flame photometry. In vivo renal hemodynamic measurements on mice were performed as previously described for rats with minor modifications (21). Arterial blood samples were taken at the end of the urine collection period. Renal hemodynamic parameters were calculated as described (19). Measurement of blood pressure was performed in anesthetized mice by the tail-cuff plethysmography method as described (17). All experiments reported were conducted as stated in the National Institutes of Health Guide For The Care And Use Of Laboratory Animals (Institute of Laboratory Animal Resources, National Academy Press, Washington DC, 1996) and were approved by a local animal care and use committee.
Histological and morphometric analysis. For histological studies, kidneys were fixed in alcoholic Bouin's solution, embedded in paraffin, sectioned at 4 µm, and stained with hematoxylin according to routine histological staining (22). Morphometric measurements of the different glomerular and capillary surfaces were performed by using an automated image-analyzing system as previously described in detail (10).
Isolation of glomeruli and cGMP measurements. Glomeruli were obtained as described previously (14). cGMP content was measured as previously described (28) using an EIA-kit from Cayman Chemical (Ann Arbor, MI).
Statistical analysis.
Values are expressed as means ± SD. Data were compared using SPSS
software (SPSS Science; Chicago, IL). ANOVA with post hoc Tukey's
-test was performed for comparison between groups. P values <0.05 were considered as significant.
| |
RESULTS |
|---|
|
|
|---|
B2
/
mice are genetically comparable to
C57Bl/6J mice.
After homogenization of the genetic background of
B2
/
mice by 10 backcrosses, microsatellite
analysis showed that B2
/
mice are now
genetically comparable to C57BL/6J mice (Table 1). C57BL/6J mice were
used as control mice in all experiments.
B2
/
mice display normal renal and
systemic hemodynamic parameters.
It is well known that bradykinin, via the B2 receptor,
induces vasodilatation and is natriuretic and diuretic. However, no difference was observed in BP, heart rate (HR), renal plasma flow (RPF), GFR, and RVR between wild-type and
B2
/
mice (Fig. 1). A 3-day metabolic study
(Table 2) showed that body weight, food
and water intake, urinary flow, urine sodium and potassium
excretion, as well as osmolality, did not differ significantly between
both groups. However, nitrite excretion was significantly reduced in
B2
/
mice (0.13 ± 0.01 µmol/24 h)
compared with wild-type mice (0.79 ± 0.12 µmol/24 h,
P < 0.01).
|
|
B2
/
mice have a decreased glomerular
capillary surface area.
No difference in the histological structure of the kidney was observed
between B2
/
and wild-type mice. Wild-type
and B2
/
mice had the same number of
glomeruli (respectively 88.8 ± 6 and 88.3 ± 5 per kidney
section, n = 10). However, morphometrical analysis of
at least 40 glomeruli per kidney section showed that the
B2
/
mice have a reduced glomerular tuft
area, which is caused by a decreased capillary surface area of 25 ± 8% (Fig. 2). In contrast, the
glomerular surface area was not different between both mice strains.
|
Glomeruli of B2
/
mice have reduced cGMP
levels.
As shown by the metabolic study, B2
/
mice
had a decreased urinary nitrite excretion, which was associated with a
decrease in the glomerular capillary surface area, suggesting a
preconstricted mesangium due to decreased vasodilatory factor levels.
To further explore this hypothesis, we studied basal and the stimulated
production of cGMP in isolated mouse glomeruli. As shown in Fig.
3, a significant (50%) decrease in basal
cGMP levels was observed in isolated glomeruli of
B2
/
mice compared with wild-type mice. When
the glomeruli were stimulated with calcium ionophore A23187, an
increase in the cGMP content was observed in both wild-type and
B2
/
mice. The ionophore-induced cGMP
production was significantly higher in wild-type than in
B2
/
mice, although the relative increase in
cGMP levels between both mouse strains was comparable.
|
| |
DISCUSSION |
|---|
|
|
|---|
The main goal of this study was to determine, on a homogenized
genetic background, renal function and morphology of
B2
/
and wild-type mice. Consistent with
previous reports (1, 6, 18, 29), we found that under
physiological conditions B2
/
mice have
normal BP and a normal HR. We thus confirm on a genetically controlled
background that under physiological conditions, i.e normal sodium diet,
the bradykinin B2 receptor plays a minor role in BP
regulation. It is, however, difficult to exclude compensatory mechanisms for the absence of the B2 receptor in these
mice. However, on a mixed J129sv × C57Bl/6J genetic background,
there was no modification of the renin-angiotensin system in
B2
/
mice (15).
To obtain more insight in the in vivo renal function and morphology of
B2
/
mice, we performed a metabolic study,
determined several renal parameters, performed classical
histomorphology, and determined a number of glomerular morphological
parameters. As previously reported (1, 7, 18), GFR, RPF,
and RVR were not different between both strains. Furthermore, the
majority of the urinary parameters was comparable between wild-type and
B2
/
mice. However, a significantly lower
urinary NO2 excretion was observed in
B2
/
mice. Classic kidney histomorphological
analysis did not show any difference between
B2
/
and wild-type mice. But glomerular
morphology analysis of a large number of glomeruli showed a significant
decrease in the size of the glomerular tuft area, which could be
attributed to a decreased capillary surface of ~20%. Interestingly
and consistent with our data, a reduction of the glomerular tuft area
was found in mice having three copies of the angiotensin I-converting
enzyme (ACE) (11). Indeed, because ACE has a higher
affinity for bradykinin than for angiotensin I (12),
overexpression of ACE could result in a decreased bradykinin
concentration and, as a consequence, mimic the reduced glomerular tuft
area observed in B2
/
animals. The decreased
urinary nitrite concentration in B2
/
mice
suggests impaired nitric oxide (NO) release in this strain, which could
account for the observed reduced glomerular tuft area. In the
B2
/
mice, it is possible that bradykinin,
normally generating NO, is no longer able to counteract the action of
endogenous vasoconstrictors, such as angiotensin II.
To verify that this decrease in the glomerular tuft area might be due
to an impaired release of NO and not to anatomic abnormalities, we have
measured the cGMP content in isolated glomeruli under basal and
stimulated conditions. We found a net 50% decrease in basal cGMP
content in the glomeruli of B2
/
mice
compared with wild-type mice. Moreover, stimulation of the isolated
glomeruli with the calcium ionophore A23187 produced a higher increase
in cGMP content in wild-type glomeruli than in glomeruli of
B2
/
mice, indicating a functional but
reduced NO-cGMP pathway in the B2
/
animals.
This lower cGMP production observed in isolated glomeruli under basal
conditions can explain the decrease in capillary tuft area in the
B2
/
mice, but it is without consequences on
the renal function at least under physiological conditions.
Interestingly, when stimulated by the calcium-ionophore, the cGMP
content is still inferior in B2
/
compared
with wild-type mice. These data reinforce the hypothesis suggested by
others that impairment in the NO-cGMP pathway is an important reason
why B2
/
mice are less resistant to
pathological insults. Indeed, indirect evidence has suggested that the
B2
/
mice have an impaired ability to
release NO. Alfie et al. (1) also proposed an impaired
ability to release NO to explain the shift to the right of the mean
arterial pressure curve in response to acetylcholine in
B2
/
mice compared with control mice.
Furthermore, based on data obtained after NO synthase blockade by
NG-nitro-L-arginine methyl ester,
this impaired ability to release NO could also explain the enhanced
susceptibility to angiotensin II-induced hypertension
(7). Reduced NO release could also explain the
increased RVR recently reported in B2
/
mice
(29). We were, however, not able to detect any significant variation in the RVR. These authors, who have also homogenized the
genetic background of their animals, have used female mice, whereas we
have used male mice. Moreover their animals were 12 wk older than the
animals that we used. It is thus possible that B2
/
mice develop, with age, an increased
RVR, which is, at the kidney level, without functional consequence at 2 mo but becomes detectable at 5 mo. This progressive increase in RVR
could be explained by the absence of the physiological tonic
vasodilatory effect of bradykinin in these mice mainly due to this
impaired NO-cGMP pathway. Consistent with the above data, it has been
recently reported that transgenic mice overexpressing the
B2 receptor have increased renal hemodynamic parameters
(increase in RBF and GFR), which was associated to an increased urinary
NO2 and NO3 excretion (30).
In summary, we have shown that in our B2
/
mice, under physiological conditions, the B2 bradykinin
receptor was not necessary to maintain normal blood pressure, renal
hemodynamics, and salt balance. Nevertheless, the
B2
/
mice, compared with wild-type animals
on the same genetic background, exhibit significant spontaneous
differences in terms of reduced glomerular tuft area associated with a
lower urinary NO2 excretion.
Apparently, thus without significant consequence under physiological
conditions, the bradykinin B2 receptor has been shown, using B2
/
mice, to play an important role
under different pathological conditions, including hypertension, heart
failure, angiogenesis, and kidney fibrosis (5, 8, 22, 26, 31,
32).
| |
ACKNOWLEDGEMENTS |
|---|
We are grateful to M. J. Fouque and M. T. Garelli for technical assistance.
| |
FOOTNOTES |
|---|
This work was supported by the Institut National de la Santé et de la Recherchè Médicale. Johan Duchene is a recipient of a fellowship from the Ministère de la Recherche et de la Technologie.
Address for reprint requests and other correspondence: J. L. Bascands, INSERM U388, Institut Louis Bugnard, CHU Rangueil, 31052 Toulouse, France (E-mail: bascalou{at}toulouse.inserm.fr).
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
First published January 30, 2003;10.1152/ajpheart.01150.2002
Received 30 December 2002; accepted in final form 24 January 2003.
| |
REFERENCES |
|---|
|
|
|---|
1.
Alfie, ME,
Sigmon DH,
Pomposiello SI,
and
Carretero OA.
Effect of high salt intake in mutant mice lacking bradykinin-B2 receptors.
Hypertension
29:
483-487,
1997
2.
Beierwaltes, WH,
Carretero OA,
and
Scicli AG.
Renal hemodynamics in response to a kinin analogue antagonist.
Am J Physiol Renal Fluid Electrolyte Physiol
255:
F408-F414,
1988
3.
Bhoola, KD,
Figueroa CD,
and
Worthy K.
Bioregulation of kinins: kallikreins, kininogens, and kininases.
Pharmacol Rev
44:
1-80,
1992[ISI][Medline].
4.
Borkowski, JA,
Ransom RW,
Seabrook GR,
Trumbauer M,
Chen H,
Hill RG,
Strader CD,
and
Hess JF.
Targeted disruption of a B2 bradykinin receptor gene in mice eliminates bradykinin action in smooth muscle and neurons.
J Biol Chem
270:
13706-13710,
1995
5.
Brochu, I,
Labonte J,
Bkaily G,
and
D'Orleans-Juste P.
Role of endothelin receptors in the hypertensive state of kinin B(2) knockout mice subjected to a high-salt diet.
Clin Sci (Lond)
103, Suppl 48:
380S-384S,
2002[Medline].
6.
Cervenka, L,
Harrison-Bernard LM,
Dipp S,
Primrose G,
Imig JD,
and
El-Dahr SS.
Early onset of salt-sensitive hypertension in bradykinin B(2) receptor null mice.
Hypertension
34:
176-180,
1999
7.
Cervenka, L,
Maly J,
Karasova L,
Simova M,
Vitko S,
Hellerova S,
Heller J,
and
El-Dahr SS.
Angiotensin II-induced hypertension in bradykinin B2 receptor knockout mice.
Hypertension
37:
967-973,
2001
8.
Emanueli, C,
Bonaria Salis M,
Figueroa C,
Chao J,
Chao L,
Gaspa L,
Capogrossi MC,
and
Madeddu P.
Participation of kinins in the captopril-induced inhibition of intimal hyperplasia caused by interruption of carotid blood flow in the mouse.
Br J Pharmacol
130:
1076-1082,
2000[ISI][Medline].
9.
Grider, J,
Falcone J,
Kilpatrick E,
Ott C,
and
Jackson B.
Effect of bradykinin on NaCl transport in the medullary thick ascending limb of the rat.
Eur J Pharmacol
287:
101-104,
1995[ISI][Medline].
10.
Heudes, D,
Michel O,
Chevalier J,
Scalbert E,
Ezan E,
Bariety J,
Zimmerman A,
and
Corman B.
Effect of chronic ANG I-converting enzyme inhibition on aging processes. I. Kidney structure and function.
Am J Physiol Regul Integr Comp Physiol
266:
R1038-R1051,
1994
11.
Huang, W,
Gallois Y,
Bouby N,
Bruneval P,
Heudes D,
Belair MF,
Krege JH,
Meneton P,
Marre M,
Smithies O,
and
Alhenc-Gelas F.
Genetically increased angiotensin I-converting enzyme level and renal complications in the diabetic mouse.
Proc Natl Acad Sci USA
98:
13330-13334,
2001
12.
Jaspard, E,
Wei L,
and
Alhenc-Gelas F.
Differences in the properties and enzymatic specificities of the two active sites of angiotensin I-converting enzyme (kininase II). Studies with bradykinin and other natural peptides.
J Biol Chem
268:
9496-9503,
1993
13.
Lortie, M,
Regoli D,
Rhaleb NE,
and
Plante GE.
The role of B1- and B2-kinin receptors in the renal tubular and hemodynamic response to bradykinin.
Am J Physiol Regul Integr Comp Physiol
262:
R72-R76,
1992
14.
MacKay, K,
Striker LJ,
Elliot S,
Pinkert CA,
Brinster RL,
and
Striker GE.
Glomerular epithelial, mesangial, and endothelial cell lines from transgenic mice.
Kidney Int
33:
677-684,
1988[ISI][Medline].
15.
Madeddu, P,
Varoni MV,
Palomba D,
Emanueli C,
Demontis MP,
Glorioso N,
Dessi-Fulgheri P,
Sarzani R,
and
Anania V.
Cardiovascular phenotype of a mouse strain with disruption of bradykinin B2 receptor gene.
Circulation
96:
3570-3578,
1997
16.
Marceau, F,
Hess JF,
and
Bachvarov DR.
The B1 receptors for kinins.
Pharmacol Rev
50:
357-386,
1998
17.
Marin-Castano, ME,
Schanstra JP,
Neau E,
Praddaude F,
Pecher C,
Ader JL,
Girolami JP,
and
Bascands JL.
Induction of functional bradykinin B(1)-receptors in normotensive rats and mice under chronic angiotensin-converting enzyme inhibitor treatment.
Circulation
105:
627-632,
2002
18.
Milia, AF,
Gross V,
Plehm R,
De Silva JA, Jr,
Bader M,
and
Luft FC.
Normal blood pressure and renal function in mice lacking the bradykinin B(2) receptor.
Hypertension
37:
1473-1479,
2001
19.
Praddaude, F,
Tack I,
Emond C,
Bascands JL,
Girolami JP,
Tran-Van T,
Regoli D,
and
Ader JL.
In vivo and in vitro homologous desensitization of rat glomerular bradykinin B2 receptors.
Eur J Pharmacol
294:
173-182,
1995[ISI][Medline].
20.
Regoli, D,
and
Barabe J.
Pharmacology of bradykinin and related kinins.
Pharmacol Rev
32:
1-46,
1980[ISI][Medline].
21.
Schanstra, JP,
Marin-Castano ME,
Praddaude F,
Tack I,
Ader JL,
Girolami JP,
and
Bascands JL.
Bradykinin B(1) receptor-mediated changes in renal hemodynamics during endotoxin-induced inflammation.
J Am Soc Nephrol
11:
1208-1215,
2000
22.
Schanstra, JP,
Neau E,
Drogoz P,
Arevalo Gomez MA,
Lopez Novoa JM,
Calise D,
Pecher C,
Bader M,
Girolami JP,
and
Bascands JL.
In vivo bradykinin B2 receptor activation reduces renal fibrosis.
J Clin Invest
110:
371-379,
2002[ISI][Medline].
23.
Scicli, AG,
and
Carretero OA.
Renal kallikrein-kinin system.
Kidney Int
29:
120-130,
1986[ISI][Medline].
24.
Margolius, HS.
Kallikreins and kinins. Some unanswered questions about system characteristics and roles in human disease.
Hypertension
26:
221-229,
1995
25.
Sigmund, CD.
Viewpoint: are studies in genetically altered mice out of control?
Arterioscler Thromb Vasc Biol
20:
1425-1429,
2000
26.
Silvestre, JS,
Bergaya S,
Tamarat R,
Duriez M,
Boulanger CM,
and
Levy BI.
Proangiogenic effect of angiotensin-converting enzyme inhibition is mediated by the bradykinin B(2) receptor pathway.
Circ Res
89:
678-683,
2001
27.
Siragy, HM.
Evidence that intrarenal bradykinin plays a role in regulation of renal function.
Am J Physiol Endocrinol Metab
265:
E648-E654,
1993
28.
Tack, I,
Marin-Castano E,
Bascands JL,
Pecher C,
Ader JL,
and
Girolami JP.
Cyclosporine A-induced increase in glomerular cyclic GMP in rats and the involvement of the endothelin B receptor.
Br J Pharmacol
121:
433-440,
1997[ISI][Medline].
29.
Trabold, F,
Pons S,
Hagege AA,
Bloch-Faure M,
Alhenc-Gelas F,
Giudicelli JF,
Richer-Giudicelli C,
and
Meneton P.
Cardiovascular phenotypes of kinin B2 receptor- and tissue kallikrein-deficient mice.
Hypertension
40:
90-95,
2002
30.
Wang, D,
Yoshida H,
Song Q,
Chao L,
and
Chao J.
Enhanced renal function in bradykinin B(2) receptor transgenic mice.
Am J Physiol Renal Physiol
278:
F484-F491,
2000
31.
Yang, XP,
Liu YH,
Scicli GM,
Webb CR,
and
Carretero OA.
Role of kinins in the cardioprotective effect of preconditioning: study of myocardial ischemia/reperfusion injury in B2 kinin receptor knockout mice and kininogen-deficient rats.
Hypertension
30:
735-740,
1997
32.
Yang, XP,
Liu YH,
Mehta D,
Cavasin MA,
Shesely E,
Xu J,
Liu F,
and
Carretero OA.
Diminished cardioprotective response to inhibition of angiotensin-converting enzyme and angiotensin II type 1 receptor in B(2) kinin receptor gene knockout mice.
Circ Res
88:
1072-1079,
2001
This article has been cited by other articles:
![]() |
M. Buleon, J. Allard, A. Jaafar, F. Praddaude, Z. Dickson, M.-T. Ranera, C. Pecher, J.-P. Girolami, and I. Tack Pharmacological blockade of B2-kinin receptor reduces renal protective effect of angiotensin-converting enzyme inhibition in db/db mice model Am J Physiol Renal Physiol, May 1, 2008; 294(5): F1249 - F1256. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Allard, M. Buleon, E. Cellier, I. Renaud, C. Pecher, F. Praddaude, M. Conti, I. Tack, and J.-P. Girolami ACE inhibitor reduces growth factor receptor expression and signaling but also albuminuria through B2-kinin glomerular receptor activation in diabetic rats Am J Physiol Renal Physiol, October 1, 2007; 293(4): F1083 - F1092. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Cayla, M. Todiras, R. Iliescu, V. V. Saul, V. Gross, B. Pilz, G. Chai, V. F. Merino, J. B. Pesquero, O. C. Baltatu, et al. Mice deficient for both kinin receptors are normotensive and protected from endotoxin-induced hypotension FASEB J, June 1, 2007; 21(8): 1689 - 1698. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. A. Skidgel, F. Alhenc-Gelas, and W. B. Campbell Regulation of Cardiovascular Signaling by Kinins and Products of Similar Converting Enzyme Systems: Prologue: Kinins and related systems. New life for old discoveries Am J Physiol Heart Circ Physiol, June 1, 2003; 284(6): H1886 - H1891. [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |